ACAD
38.12
+0.09
+0.24%
AEMD
0.196
-0.01
-4.6341%
APRI
1.81
+0.04
+2.26%
ARNA
4.57
-0.07
-1.51%
ATEC
1.42
-0.01
-0.70%
CNAT
6.38
-0.05
-0.78%
CRXM
0.323
-0.027
-7.85428%
CYTX
1.12
+0.01
+0.90%
DXCM
68.42
+1.02
+1.51%
GNMK
10.85
-0.01
-0.09%
HALO
15.89
+0.59
+3.86%
ILMN
193.18
+2.02
+1.06%
INNV
0.145
-0.005
-3.333%
INO
10.32
+0.28
+2.79%
ISCO
0.062
+0.005
+8.9474%
ISIS
65.16
-0.17
-0.26%
LGND
85.4
-0.45
-0.52%
LPTN
2.26
0.00
0.00%
MBVX
3.35
-0.2
-5.63%
MEIP
2.39
+0.27
+12.74%
MNOV
4.08
-0.37
-8.31%
MRTX
27.87
+0.28
+1.01%
MSTX
0.491
+0.019
+4.025%
NBIX
42.95
+0.46
+1.08%
NUVA
43.4
+1.85
+4.45%
ONCS
0.307
-0.003
-0.968%
ONVO
4.68
+0.12
+2.63%
OREX
7.55
+0.01
+0.13%
OTIC
33.09
+1.23
+3.86%
QDEL
23.55
-0.15
-0.63%
RCPT
169.87
+2.49
+1.49%
RGLS
17.18
-0.12
-0.69%
RMD
72.92
+1.04
+1.45%
SCIE
0.021
-0.004
-15.6000%
SPHS
0.797
-0.013
-1.6296%
SRNE
11.06
-0.25
-2.21%
TROV
8.85
+0.32
+3.75%
VICL
0.94
0.00
0.00%
VOLC
17.99
0.00
0.00%
ZGNX
1.62
+0.04
+2.53%
ACAD
38.12
+0.09
+0.24%
AEMD
0.196
-0.01
-4.6341%
APRI
1.81
+0.04
+2.26%
ARNA
4.57
-0.07
-1.51%
ATEC
1.42
-0.01
-0.70%
CNAT
6.38
-0.05
-0.78%
CRXM
0.323
-0.027
-7.85428%
CYTX
1.12
+0.01
+0.90%
DXCM
68.42
+1.02
+1.51%
GNMK
10.85
-0.01
-0.09%
HALO
15.89
+0.59
+3.86%
ILMN
193.18
+2.02
+1.06%
INNV
0.145
-0.005
-3.333%
INO
10.32
+0.28
+2.79%
ISCO
0.062
+0.005
+8.9474%
ISIS
65.16
-0.17
-0.26%
LGND
85.4
-0.45
-0.52%
LPTN
2.26
0.00
0.00%
MBVX
3.35
-0.2
-5.63%
MEIP
2.39
+0.27
+12.74%
MNOV
4.08
-0.37
-8.31%
MRTX
27.87
+0.28
+1.01%
MSTX
0.491
+0.019
+4.025%
NBIX
42.95
+0.46
+1.08%
NUVA
43.4
+1.85
+4.45%
ONCS
0.307
-0.003
-0.968%
ONVO
4.68
+0.12
+2.63%
OREX
7.55
+0.01
+0.13%
OTIC
33.09
+1.23
+3.86%
QDEL
23.55
-0.15
-0.63%
RCPT
169.87
+2.49
+1.49%
RGLS
17.18
-0.12
-0.69%
RMD
72.92
+1.04
+1.45%
SCIE
0.021
-0.004
-15.6000%
SPHS
0.797
-0.013
-1.6296%
SRNE
11.06
-0.25
-2.21%
TROV
8.85
+0.32
+3.75%
VICL
0.94
0.00
0.00%
VOLC
17.99
0.00
0.00%
ZGNX
1.62
+0.04
+2.53%
Home » Archive by Category

Syndication

Product Development Associate 3 (Pacific Beach)

April 17, 2015 – 11:01 am

Function/Scope:
The Development Associate 3 will be responsible, without daily supervisorial contact, for the preparation and interpretation of scientific assay or process development experiments relating to bioreactor development, product testing, […

Product Development Associate 3 (Pacific Beach)

April 17, 2015 – 11:01 am

Function/Scope:
The Development Associate 3 will be responsible, without daily supervisorial contact, for the preparation and interpretation of scientific assay or process development experiments relating to bioreactor development, product testing, […

Artificial Blood Vessel Lets Researchers Better Assess Clot Removal Devices

April 17, 2015 – 10:56 am

Researchers at the University of California, San Diego School of Medicine have created an in vitro, live-cell artificial vessel that can be used to study both the application and effects of devices used to extract life-threatening blood clots in the br…

Senior Sensor Scientist — San Diego- electrochemistry- Enzymes related (Carlsbad, CA)

April 17, 2015 – 10:40 am

JOB #: 114653-T
Join this innovator in medical electronics. My client develops, manufactures and markets point of care blood analysis systems to include blood gas analysis, transcutaneous monitoring and immunoassay testing.
Job Duties:
? Developin […

Senior Sensor Scientist — San Diego- electrochemistry- Enzymes related (Carlsbad, CA)

April 17, 2015 – 10:40 am

JOB #: 114653-T
Join this innovator in medical electronics. My client develops, manufactures and markets point of care blood analysis systems to include blood gas analysis, transcutaneous monitoring and immunoassay testing.
Job Duties:
? Developin […

Sr. Financial Analyst – Thermo Fisher Scientific – Carlsbad, CA

April 17, 2015 – 10:15 am

This is a critical to organization role with high visibility to the greater finance organization as well as the commercial leadership team….
From Thermo Fisher Scientific – 17 Apr 2015 17:15:56 GMT
– View all Carlsbad jobs

Senior EHS Consultant

April 17, 2015 – 8:30 am

CA-Laguna Hills, . MAKE A POSTIVE IMPACT ON THE WORLD EVERY DAY Our Southern California Region (Laguna Hills or Oxnard, CA) is looking for an experienced EHS Professional with 7 to 10 years of experience in EHS consulting and/or corporate EHS program m…

Environmental Health Safety & Sustainabilty Consulting – Business Development

April 17, 2015 – 8:29 am

CA-Laguna Hills, . MAKE A POSITIVE IMPACT ON THE WORLD EVERY DAY This senior level consultant will be instrumental in helping to grow our Southern California Environmental Health Safety and Sustainability Consulting business. This exciting position has both business development and technical consulting responsibilities, so we are looking for a unique individual who has both senior level technical EHS&S expertise,

Scientist/Scientist II, R&D (Sorrento Valley, Ca)

April 17, 2015 – 8:03 am

Essential Functions:
Develop and validate high-throughput assays for biomedical research.
Design and perform experiments aimed to address key feasibility questions, optimize and troubleshoot assays.
Participate in development of experimental […

Trovagene’s Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients

April 17, 2015 – 7:30 am

Non-invasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and months before detection of cancer progression with imagingTracking circulating tumor DNA (ctDNA) in urine enables determination of response to novel EGFR T790M inhibitors within days of initial treatmentOral presentation selected for Best Abstracts session at the 2015 European Lung Cancer Conference

SAN DIEGO, April 17, 2015 /PRNewswire/ — Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that clinical data presented at the 2015 European Lung Cancer Conference (ELCC) demonstrate that its urine-based Precision Cancer Monitoring (PCM) platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. The abstract, titled Detection of EGFR T790M Mutation in Urinary Circulating Tumor DNA from Metastatic Non-Small Cell Lung Cancer Patients, was presented today by Hatim Husain, M.D., University of California, San Diego Moores Cancer Center during the ESMO-IASLC Best Abstracts session in Geneva, Switzerland.

In an interim analysis of 34 patients from an ongoing clinical study, Trovagene’s PCM platform detected the T790M mutation in all patients who were positive for the mutation in tissue biopsy. The Company’s urine-based assay identified additional patients as T790M-positive, including those who had clinical suspicion of T790M-progressive disease, but were either negative by tissue biopsy or had not yet undergone tissue biopsy for confirmation. Trovagene’s PCM platform detected EGFR T790M resistance mutations months earlier than radiologic detection of progression in patients.

Early pharmacodynamic events occurring within hours or days of anti-EGFR drug treatment were evaluated in the study by implementing daily monitoring of urinary ctDNA. Initial results demonstrated that immediate changes in EGFR mutational load using a urine specimen may identify patients who respond to anti-EGFR therapy much earlier than with follow-up CT-scans. This new clinical utility of urinary ctDNA is being further validated in a larger patient cohort.

“These interim results suggest that use of urinary ctDNA has potential to detect EGFR T790M status in a higher number of study subjects and may make some patients eligible for therapy who would by tissue biopsy be falsely classified as negative,” stated Dr. Husain. “Detecting the emergence of EGFR T790M mutations before progression has the potential to enable physicians to better align therapeutic selection and inform early therapeutic decision making.”

Added Antonius Schuh, PhD, chief executive officer of Trovagene, “These compelling data using a completely non-invasive specimen support the potential of our PCM platform to transform the way clinicians monitor and treat lung cancer patients. Last year, we showed that we could detect and monitor the BRAF V600E mutation in histiocytic disease and change the way clinicians diagnose and treat Erdheim-Chester disease. Today we are following the same course in lung cancer by identifying more patients with driver mutations, observing the immediate effects of targeted therapy, and tracking a key resistance mutation. We continue to add to the body of clinical evidence supporting our proprietary liquid biopsy platform for cancer monitoring, and remain focused on improving the standard of cancer care.”

About The T790M Mutation in Non-Small Cell Lung Cancer

While lung cancer is one of the most aggressive malignancies, progress has been made in the advancement of therapeutic strategies against the disease. In particular, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, in non–small cell lung cancer (NSCLC) patients with EGFR mutations have demonstrated clinical response rates as high as 80%. However, after about 6 to 12 months, most tumors develop acquired resistance to these targeted therapies. Research into such resistance has identified the secondary T790M mutation, which occurs in approximately 60% of patients with acquired resistance to EGFR-TKIs and is reported to negate the benefits of treatment. To date, no effective treatment options have been approved for NSCLC patients with the T790M mutation, however new targeted drug candidates such as rociletinib and AZD9291 are in advanced clinical development, and have shown promise for this indication.

European Lung Cancer Conference – 15 – 18 Apr 2015

The European Society for Medical Oncology (ESMO) and The International Association for the Study of Lung Cancer (IASLC) recently announced that the European Lung Cancer Conference (ELCC), will become an annual meeting as of 2015. ELCC will encourage cooperation with the most important societies representing thoracic oncology specialists, forming a truly multidisciplinary team and reinforcing the science, education and practice of lung cancer treatment across Europe and beyond.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine.  The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s Precision Cancer MonitoringSM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2014 and other periodic reports filed with the Securities and Exchange Commission.

Trovagene Contacts

Investor Relations

Media Relations

David Moskowitz and Amy Caterina

Investor Relations

Ian Stone

Account Director

Trovagene, Inc.

Canale Communications, Inc.

858-952-7593

619-849-5388

ir@trovagene.com

ian@canalecomm.com

Logo – http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

SOURCE Trovagene, Inc.